We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Kidney Biopsy Profiles Predict Delayed Graft Function

By LabMedica International staff writers
Posted on 28 Feb 2018
The probability of renal graft failure can be assessed for donor kidney biopsies through histological analyses; the potential for delayed graft function is not as easily determined by morphology alone, but could potentially be aided by molecular analysis.

A scientific team led by those at Harvard University Office of Technology Development (Cambridge, MA; USA) used donor renal biopsies for both histological assessments and gene expression analysis. More...
RNA was extracted from tissue and reverse transcribed to complementary DNA (cDNA), which was combined with primers designed for genes that were chosen based on literature review related to delayed graft function.

The scientists used quantitative real-time polymerase chain reaction (PCR) to perform gene expression analyses, comparing biopsies from 16 kidneys that showed primary function upon transplantation with those 16 exhibiting delayed graft function. Delayed graft function described the condition of a patient requiring dialysis within a week of transplantation. From the set of genes that the team selected for comparison between the two renal biopsy groups, there were four that showed increased expression within the delayed graft function biopsy samples.

One of the four genes expressed more highly in delayed graft function samples was annotated as a gene for matrix metallopeptidase 3 (MMP3; stromelysin 1, progelatinase), which are related to inflammation and immune response. The other three genes showing more expression with delayed graft function were categorized as related to metabolism, and they were annotated as retinol-binding protein 4, plasma (RBP4); cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4 (CYP3A4); and fatty acid binding protein 1, liver (FABP1). For delayed graft function samples, these four genes showed increased expression from about 2.5- to 4.0-fold each. In comparison, for samples with immediate function, expression of these four genes hovered around 1.0-fold, with some signals slightly below 1.0 or between 1.0- and 2.0-fold.

The authors concluded that the results of their study indicated a possible gene fingerprint, with potential to forecast likelihood of delayed graft function for donor renal tissue. They recommended further research to assess the value of this approach in conjunction with existing protocols. The study was presented at the Annual Cutting Edge of Transplantation (CEOT) Meeting held February 8-10, 2018. Phoenix, AZ, USA.

Related Links:
Harvard University Office of Technology Development


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Portable POCT Blood Gas Analyzer
BD100
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.